WHAT IS CLAIMED IS:

1. A mesenchymal stromal cell (MSC) comprising:

(1) exogenous nucleic acid encoding a chimeric antigen receptor (CAR) targeting an epithelial-specific antigen, wherein said MSC expresses said CAR, and

(2a) an elevated level of a polypeptide selected from the group consisting of a nuclear factor kappa B subunit 1 (NFκB1) polypeptide, a Jun proto-oncogene (JUN) polypeptide, a transcription factor RelB (RELB) polypeptide, an interferon regulatory factor 1 (IRF1) polypeptide, a tumor necrosis factor (TNF) α polypeptide, an interleukin (IL)-10 polypeptide, a fibroblast growth factor (FGF)-2 polypeptide, a granulocyte colony stimulating factor (G-CSF) polypeptide, a granulocyte-macrophage colony-stimulating factor (GM-CSF) polypeptide, an eotaxin polypeptide, a galectin 9 (Gal-9) polypeptide, a programmed cell death protein 1 (PD-1) polypeptide, a T-cell immunoglobin mucin-3 (TIM-3) polypeptide, a CXC chemokine receptor (CXCR) 3 polypeptide, and a CXCR4 polypeptide, or

(2b) an elevated level of a polypeptide selected from the group consisting of a NFκB1 polypeptide, a JUN polypeptide, a RELB polypeptide, an IRF1 polypeptide, a TNFα polypeptide, a cytotoxic T-lymphocyte-associated-protein 4 (CTLA4), a toll-like receptor 3 (TLR3), a toll-like receptor 4 (TLR4), a toll-like receptor 9 (TLR9), a tumor necrosis factor receptor 2 (TNFR2) polypeptide, an IL-10 polypeptide, a FGF-2 polypeptide, a G-CSF polypeptide, a GM-CSF polypeptide, an eotaxin polypeptide, a Gal-9 polypeptide, a PD-1 polypeptide, a TIM-3 polypeptide, a CXCR3 polypeptide, and a CXCR4 polypeptide.

2. The MSC of claim 1, wherein said MSC is a human MSC.

3. The MSC of claim 1, wherein said MSC is an adipose derived-MSC.

4. The MSC of claim 1, wherein said epithelial-specific antigen is E-cadherin (Ecad).

5. The MSC of claim 1, wherein said MSC comprises said (2a).

6. The MSC of claim 5, wherein said MSC comprises exogenous nucleic acid encoding said polypeptide of said (2a), wherein said MSC expresses said polypeptide of said (2a).

7. The MSC of claim 1, wherein said MSC comprises said (2b).

8. The MSC of claim 7, wherein said MSC comprises exogenous nucleic acid encoding said polypeptide of said (2b), wherein said MSC expresses said polypeptide of said (2b).

9. A composition comprising a MSC comprising:

(1) exogenous nucleic acid encoding a CAR targeting an epithelial-specific antigen, wherein said MSC expresses said CAR, and

(2a) an elevated level of a polypeptide selected from the group consisting of a NFκB1 polypeptide, a JUN polypeptide, a RELB polypeptide, an IRF1 polypeptide, a TNFα polypeptide, an IL-10 polypeptide, a FGF-2 polypeptide, a G-CSF polypeptide, a GM-CSF polypeptide, an eotaxin polypeptide, a Gal-9 polypeptide, a PD-1 polypeptide, a TIM-3 polypeptide, a CXCR 3 polypeptide, and a CXCR4 polypeptide, or

(2b) an elevated level of a polypeptide selected from the group consisting of a NFκB1 polypeptide, a JUN polypeptide, a RELB polypeptide, an IRF1 polypeptide, a TNFα polypeptide, a CTLA4, a TLR3, a TLR4, a TLR9, a TNFR2 polypeptide, an IL-10 polypeptide, a FGF-2 polypeptide, a G-CSF polypeptide, a GM-CSF polypeptide, an eotaxin polypeptide, a Gal-9 polypeptide, a PD-1 polypeptide, a TIM-3 polypeptide, a CXCR3 polypeptide, and a CXCR4 polypeptide.

10. Use of a MSC or a composition comprising said MSC, wherein said MSC comprises:

(1) exogenous nucleic acid encoding a CAR targeting an epithelial-specific antigen, wherein said MSC expresses said CAR, and

(2a) an elevated level of a polypeptide selected from the group consisting of a NFκB1 polypeptide, a JUN polypeptide, a RELB polypeptide, an IRF1 polypeptide, a TNFα polypeptide, an IL-10 polypeptide, a FGF-2 polypeptide, a G-CSF polypeptide, a GM-CSF polypeptide, an eotaxin polypeptide, a Gal-9 polypeptide, a PD-1 polypeptide, a TIM-3 polypeptide, a CXCR 3 polypeptide, and a CXCR4 polypeptide, or

(2b) an elevated level of a polypeptide selected from the group consisting of a NFκB1 polypeptide, a JUN polypeptide, a RELB polypeptide, an IRF1 polypeptide, a TNFα polypeptide, a CTLA4, a TLR3, a TLR4, a TLR9, a TNFR2 polypeptide, an IL-10 polypeptide, a FGF-2 polypeptide, a G-CSF polypeptide, a GM-CSF polypeptide, an eotaxin polypeptide, a Gal-9 polypeptide, a PD-1 polypeptide, a TIM-3 polypeptide, a CXCR3 polypeptide, and a CXCR4 polypeptide,

in the manufacture of a medicament for (a) treating a mammal having graft versus host disease (GVHD), (b) suppressing an immune response within a mammal, or (c) reducing the number of activated T cells within a mammal.

11. The use of claim 10, wherein said mammal is a human.

12. The use of claim 15, wherein a symptom of said GVHD is reduced at least 10 percent.

13. The use of claim 15, wherein a number of regulatory T cells (Tregs) within the mammal is increased at least 10 percent.

14. The use of claim 10, wherein said use comprises suppressing said immune response within said mammal.

15. The use of claim 10, wherein said use comprises treating said mammal having GVHD.

16. The use of claim 14, wherein a number of activated T cells within the mammal is reduced at least 10 percent.

17. The use of claim 14, wherein a number of Tregs within the mammal is increased at least 10 percent.

18. The use of claim 10, wherein said use comprises reducing the number of activated T cells within said mammal.

19. The use of claim 18, wherein the number of activated T cells within the mammal is reduced at least 10 percent.

20. The use of claim 18, wherein a number of Tregs within the mammal is increased at least 10 percent.